These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24870844)

  • 1. [Biological therapy for osteoporosis].
    Nakamura S; Tanaka S
    Clin Calcium; 2014 Jun; 24(6):919-25. PubMed ID: 24870844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New targets for intervention in the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Nat Rev Rheumatol; 2011 Sep; 7(11):631-8. PubMed ID: 21931340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis: now and the future.
    Rachner TD; Khosla S; Hofbauer LC
    Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
    Sims NA; Ng KW
    Curr Osteoporos Rep; 2014 Mar; 12(1):98-106. PubMed ID: 24477416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
    Quemerais-Durieu MA; Kerlan V; Chabre O
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel strategies for the development of anabolic agents for treatment of osteoporosis].
    Saeki M; Egusa H
    Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):277-80. PubMed ID: 25492363
    [No Abstract]   [Full Text] [Related]  

  • 10. Future directions for new medical entities in osteoporosis.
    Ferrari S
    Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):859-70. PubMed ID: 25432357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].
    Jakob F; Genest F; Baron G; Stumpf U; Rudert M; Seefried L
    Unfallchirurg; 2015 Nov; 118(11):925-32. PubMed ID: 26471379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Innovations in the treatment of osteoporosis].
    Tsourdi E; Hofbauer LC
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
    [No Abstract]   [Full Text] [Related]  

  • 14. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of osteoporosis with denosumab.
    Lewiecki EM
    Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoporosis treatment by anti-RANKL antibody].
    Sugimoto T
    Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Odanacatib (MK-0822)].
    Nagase Y; Tanaka S
    Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new treatment for osteoporosis using fully human monoclonal antibody to RANKL, AMG 162].
    Takahashi N; Ozawa H
    Clin Calcium; 2005 Jan; 15(1):43-8. PubMed ID: 15632472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
    Mukherjee K; Chattopadhyay N
    Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.